Preview

Cardiovascular Therapy and Prevention

Advanced search

Relationship between serum inflammatory markers and recurrent atrial fibrillation in patients undergoing pulmonary vein isolation

https://doi.org/10.15829/1728-8800-2020-2579

Abstract

Aim. To study the baseline level of inflammatory markers (IM) and proteins of serum proteolytic system in patients scheduled for pulmonary vein isolation, and to analyze the potential of IM to predict the arrhythmogenic foci outside the PV sleeves — non-pulmonary vein dependent atrial fibrillation (AF).

Material and methods. The study included 100 patients with paroxysmal (n=89) and persistent (n=11) AF who underwent the primary PV cryoballoon ablation with the simultaneous implantation of a loop recorder (Reveal XT, Medtronic). Before the procedure, we analyzed following parameters in all patients: N-terminal pro-brain natriuretic peptide (NTproBNP), matrix metalloproteinases 1, 3, 9, tissue inhibitor of matrix metalloproteinase 1, fibroblast growth factor-2, fatty acid binding protein 3, transforming growth factor p1, tumor necrosis factor a, interleukin 1p.

Results. A significant negative predictive value of baseline NTproBNP (hazard ratio, 1,00053, p=0,00935) for recurrent AF (recurrence risk increases by 8,4% with an increase in NTproBNP level by 100 pg/ml) was demonstrated. For the rest of the parameters, there was no significant effect on recurrence risk in the postoperative period.

Conclusion. The role of IM in the AF pathogenesis should be studied further, taking into account the recommended sample sizes to assess their predictive ability in relation to preoperative detection of patients with non-pulmonary vein dependent.

About the Authors

E. N. Tsareva
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow



K. V. Davtyan
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow



A. G. Topchyan
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow



M. S. Kharlap
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow



A. A. Kalemberg
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow



А. A. Brutyan
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow



I. A. Efimova
National Medical Research Center for Therapy and Preventive Medicine

Moscow



N. L. Bogdanova
National Medical Research Center for Therapy and Preventive Medicine

Moscow



References

1. . Haissaguerre M, Jais P, Shah DC, et al. Spontaneous Initiation of Atrial Fibrillation by Ectopic Beats Originating in the Pulmonary Veins. N Engl J Med. 1998;339(10):659-66. doi:10.1056/NEJM199809033391003.

2. Dedkova АА, Suslova TE, Kologrivova IV, et al. Inflamation factors and markers of myocardial damage in atrial fibrillation. Journal of arrhythmology. 2010;60:49-53. (In Russ.)

3. Hsieh FY, Lavori W. Sample-Size Calculations for the Cox Proportional Hazards Regression Model with Nonbinary Covariates. Control Clin Trials. 2000;560:552-60. doi: 10.1016/s0197-2456(00)00104-5.

4. Qiu W, Chavarro J, Lazaruset R, et al. PowerSurvEpi: Power and Sample Size Calculation for Survival Analysis of Epidemiological Studies. R package version 0.1.0. 2018. https://CRAN.R-project. org/package=powerSurvEpi.

5. Chua W, Purmah Y, Cardoso V, et al. Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. Eur Heart J. 2019;21;40(16):1268-76. doi:10.1093/eurheartj/ehy815.

6. Liew R, Khairunnisa K, Gu Y, et al. Role of tumor necrosis factor-а in the pathogenesis of atrial fibrosis and development of an arrhythmogenic substrate. Circ J. 2013;77(5): 1171-9. doi:10.1253/circj.cj-12-1155.

7. 7 Li YY, Feng YQ, Kadokami T, et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci. U.S.A. 2000; 97;23:12746-51. doi:10.1073/pnas.97.23.12746.

8. Luan Y, Guo Y, Li S, et al. Interleukin-18 among atrial fibrillation patients in the absence of structural heart disease. Europace. 2010;12(12):1713-8. doi:10.1093/europace/euq321.

9. Psychari SN, Apostolou T, Sinos L, et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol. 2005;95(6):764-7 doi:10.1016/j.amjcard.2004.11.032.

10. Nagashima K, Okumura Y, Watanabe I, et al. Does location of epicardial adipose tissue correspond to endocardial high dominant frequency or complex fractionated atrial electrogram sites during atrial fibrillation? Circ. Arrhythm. Electrophysiol. 2012;5:676-83. doi:10.1161/CIRCEP.112.971200.

11. Kanazawa H, Yamabe H, Enomoto K, et al. Importance of pericardial fat in the formation of complex fractionated atrial electrogram region in atrial fibrillation. Int J Cardiol. 2014;174:557-64. doi:10.1016/j.ijcard.2014.04.135.

12. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113:898-918. doi: 10.1161/CIRCULATIONAHA.106.171016.

13. Zhang J, Youn J, Kim Y, et al. NOX4-dependent hydrogen peroxide overproduction in human atrial fibrillation and HL-1 atrial cells: relationship to hypertension. Front Physiol. 2012;3:140. doi:10.3389/fphys.2012.00140.

14. Hori M, Nishida K. Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc Res. 2009;81:457-64. doi:10.1093/cvr/cvn335.


Review

For citations:


Tsareva E.N., Davtyan K.V., Topchyan A.G., Kharlap M.S., Kalemberg A.A., Brutyan А.A., Efimova I.A., Bogdanova N.L. Relationship between serum inflammatory markers and recurrent atrial fibrillation in patients undergoing pulmonary vein isolation. Cardiovascular Therapy and Prevention. 2020;19(5):2579. (In Russ.) https://doi.org/10.15829/1728-8800-2020-2579

Views: 697


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)